1 unchanged sentence
(c) Trading Plans
−Removed: During the quarter ended December 31, 2025, the following directors and officers (as defined in Exchange Act Rule 16a-1(f)) adopted certain trading plans intended to satisfy Rule 10b5-1(c):
+Added: During the quarter ended March 31, 2026, the following directors and officers (as defined in Exchange Act Rule 16a-1(f)) adopted certain trading plans intended to satisfy Rule 10b5-1(c):
Name Title Adoption or Termination Date Plan End Date Shares Vesting and Subject to Sell-To-Cover (1)
Other Shares Being Sold (Subject to Certain Conditions)
−Removed: Christopher Anzalone President and Chief Executive Officer 12/22/2025 01/31/2030 1,871,805 n/a
−Removed: James Hamilton Chief Medical Officer, Head of R&D 12/02/2025 03/05/2027 n/a 44,000
+Added: Victoria Vakiener Board Member 01/12/2026 12/31/2026 4,300
+Added: Adeoye Olukotun Board Member 01/14/2026 12/31/2026 7,819
+Added: Hongbo Lu Board Member 01/14/2026 12/31/2026 7,449
+Added: William Waddill Board Member 02/25/2026 12/31/2026 3,910
+Added: Daniel Apel Chief Financial Officer 03/29/2026 04/27/2027 43,750
(1) This column indicates the total number of shares vesting, but the 10b5-1 Plan provides for the sale of only those shares necessary to satisfy payment of applicable withholding taxes.
3 unchanged sentences
(incorporated by reference from Exhibit 3.2 of the Company’s Form 10-Q filed on May 2, 2023)
−Removed: 3.3* Second Amended and Restated Bylaws of Arrowhead Pharmaceuticals, Inc., as amended January 24, 2023
−Removed: A mendment No.
−Removed: 2 to Financing Agreement between Arrowhead Pharmaceuticals, Inc.
−Removed: and Sixth Street Lending Partners dated August 7, 2024
+Added: Second Amended and Restated Bylaws of Arrowhead Pharmaceuticals, Inc., as amended January 24, 2023 (incorporated by reference from Exhibit 3.3 of the Company's Form 10-Q filed on February 5, 2026)
+Added: Form of Pre-Funded Warrant (incorporated by reference from Exhibit 4.1 of the Company’s Form 8-K filed on January 9, 2026)
+Added: Indenture, dated as of January 12, 2026, between Arrowhead Pharmaceuticals, Inc.
+Added: Bank Trust Company, National Association, as trustee (incorporated by reference from Exhibit 4.1 of the Company’s Form 8-K filed on January 12, 2026)
+Added: First Supplemental Indenture, dated as of January 12, 2026, between Arrowhead Pharmaceuticals, Inc.
+Added: Bank Trust Company, National Association, as trustee (incorporated by reference from Exhibit 4.2 of the Company’s Form 8-K filed on January 12, 2026)
+Added: Form of certificate representing the 0.00% Convertible Senior Notes due 2032 (incorporated by reference from Exhibit 4.3 of the Company’s Form 8-K filed on January 12, 2026)
+Added: Arrowhead Pharmaceuticals, Inc.
+Added: Amended and Restated 2021 Incentive Plan
+Added: Arrowhead Pharmaceuticals, Inc.
+Added: Amended and Restated Inducement Plan
31.1* Certification of Chief Executive Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
14 unchanged sentences
** Furnished herewith.
+Added: # Indicates compensation plan, contract or arrangement.
† Certain portions of this exhibit were redacted by means of marking such portions with asterisks because the identified portions are (i) not material and (ii) treated as private or confidential by the Company.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Quarterly Report on Form 10-Q to be signed on its behalf by the undersigned, thereunto duly authorized.
−Removed: February 5, 2026
ARROWHEAD PHARMACEUTICALS, INC.
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.